Sagimet Biosciences (SGMT) risk factors

Item 1A of every Sagimet Biosciences Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open SGMT in Gloom →

Sagimet Biosciences' chart, financials and news, free in your browser.Open SGMT in Gloom →

FY2025 10-K risk factors
72 risks10 new8 dropped15 reworded
Sagimet faces ongoing operating losses and cash burn with $113.1 million left as of December 31, 2025. Development risks center on combination therapies, regulatory hurdles, and intense competition for products like denifanstat and TVB-3567. License partner Ascletis faces external litigation risks that could impact business operations.
Filed Mar 11, 2026
FY2024 10-K risk factors
70 risks
Sagimet Biosciences faces heavy reliance on its lead drug candidate denifanstat for treating MASH.
Filed Mar 12, 2025